budesonide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 20 Diseases   17 Trials   17 Trials   3666 News 


«12...1819202122232425262728...4243»
  • ||||||||||  budesonide / Generic mfg.
    Clinical, Journal:  Panuveitis in a patient with active Crohn's disease. (Pubmed Central) -  Mar 6, 2021   
    The patient was started on topical steroid eye drops and oral budesonide and mesalazine. Her vision improved after 3 weeks and bowel symptoms attained remission after 8 weeks, and at present, she is doing well.
  • ||||||||||  budesonide / Generic mfg.
    Enrollment change, Trial withdrawal:  Co-STAR: Coronavirus Smell Therapy for Anosmia Recovery (clinicaltrials.gov) -  Mar 1, 2021   
    P2,  N=0, Withdrawn, 
    In the presentation of this case, we aim to underscore the diagnostic challenges that clinicians face in differentiating CMUSE from other more common diagnoses, particularly NSAIDs-induced enteropathy. N=200 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  [VIRTUAL] A case of Secukinumab induced inflammatory bowel disease () -  Feb 23, 2021 - Abstract #BWG2021BWG_104;    
    The indication for combined therapy for psoriasis and IBD was established and vedolizumab was associated...(2) A pooled data analysis including 21 trials showed this adverse effect of Secukinumab to be rare but nevertheless, a new onset Crohn's disease or ulcerative colitis should be considered in patients receiving this treatment and presenting with suggestive complaints and a matching colonoscopic image. (4) This case report aims to supplement existing literature regarding this subject and to raise awareness for this rare but severe adverse effect of Secukinumab.
  • ||||||||||  budesonide / Generic mfg.
    Preclinical, Journal:  Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease. (Pubmed Central) -  Feb 10, 2021   
    The sustained release of BNP could facilitate accumulation in the inflamed tissue, enabling BNP to penetrate inflamed mucosa and release active budesonide to the target site. The multistage systems of S1MP and BNP were further evaluated in three-dimensional (3D) in vitro model of IBD and were found to (1) increase accumulation of BNP in the inflamed areas, (2) restore the barrier function of Caco-2 inflamed monolayer, and (3) significantly reduce pro-inflammatory cytokine release almost to the level of the healthy control.
  • ||||||||||  budesonide / Generic mfg.
    [VIRTUAL] ALBUMIN-BASED NANOPARTICLES FOR DURG COMBINATION IN INFLAMMATORY BOWEL DISEASE (Intestinal Inflammation, Fibrosis and Regeneration) -  Feb 5, 2021 - Abstract #CCCongress2021CCCongress_252;    
    Both small-molecule drugs and biologics were chosen to be encapsulated in these NPs, including budesonide (BUD), vancomycin (Vanco), and granulocyte macrophage colony-stimulating factor (GM-CSF)...Importantly, analyses of the physicochemical characteristics and targeting capacities of these NPs indicate that HEP coating modulates NP binding to the inflamed intestine, providing a foundation for future development of inflammation-targeting NP formulations 3. Furthermore, by analyzing disease parameters in individual mice, we also investigated the correlation between NP targeting and disease activity in the inflamed colon, which provides an approach to further our understanding on the underlying interactions between NPs and the biological interface in colitis.
  • ||||||||||  budesonide / Generic mfg.
    Journal:  Evaluation of Budesonide-Hydroxypropyl-β-Cyclodextrin Inclusion Complex in Thermoreversible Gels for Ulcerative Colitis. (Pubmed Central) -  Feb 4, 2021   
    Furthermore, by analyzing disease parameters in individual mice, we also investigated the correlation between NP targeting and disease activity in the inflamed colon, which provides an approach to further our understanding on the underlying interactions between NPs and the biological interface in colitis. Novel budesonide inclusion complex formulations improved microscopic damage and reduced colonic MPO activity and TNF-α levels.
  • ||||||||||  dexamethasone / Generic mfg., budesonide / Generic mfg.
    [VIRTUAL] Corticosteroid Hypersensitivity Skin Testing at a Large Tertiary Care Network; 2008-2018 () -  Feb 3, 2021 - Abstract #AAAAI2021AAAAI_740;    
    Hypersensitivity reactions to a specific CS were confirmed in seven patients (30%); five through a positive ST, and two patients had positive DPT after a negative ST. However, only five patients out of 18 with a negative ST underwent DPT.  Conclusions Drug provocation test should be performed in the setting of a negative ST and if the clinically suspicion is high during corticosteroid hypersensitivity evaluation.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Entyvio (vedolizumab) / Takeda
    [VIRTUAL] VEDOLIZUMAB IN STEROID REFRACTORY ACUTE GVHD () -  Jan 30, 2021 - Abstract #APBMT2020APBMT_116;    
    There is no definitive 2nd line agent for acute GVHD. Vedolizumab is a viable therapeutic option in isolated SR acute gut GVHD.
  • ||||||||||  budesonide / Generic mfg.
    FDA event, Journal:  Re-Tasking of Approved FDA Drugs for Iatrogenic Botulism Treatment: A Paired 3D-QSAR/Docking Approach. (Pubmed Central) -  Jan 23, 2021   
    In this study, we applied a well establish ligand- and structure-based methodology for the identification of hit-compounds among a database of FDA-approved drugs. The identification of budesonide, protirelin, and ciclesonide followed by the other compounds can be a starting point for the investigations upon the selected compounds without going through the long and twisted way of drug approval.
  • ||||||||||  budesonide / Generic mfg.
    Journal:  Les colites microscopiques. (Pubmed Central) -  Jan 23, 2021   
    After a first course of budesonide, recurrence of diarrhea is frequent and a maintenance therapy can be prescribed for several months. In case of intolerance or refractoriness, second-line therapy (immunosuppressants, biological therapy, surgery) should be discussed in multidisciplinary team meeting.
  • ||||||||||  budesonide / Generic mfg.
    Journal:  Serotonin in the Pathogenesis of Lymphocytic Colitis. (Pubmed Central) -  Jan 22, 2021   
    Budesonide decreased the levels of 5-HT, 5-HIAA, and TPH1 expression and the number of EECs to values that did not differ from those for controls. In conclusion, the serotonin metabolism may be important for LC pathogenesis, and the urinary level of 5-HIAA may be considered as a non-invasive marker of this disease activity.
  • ||||||||||  budesonide / Generic mfg.
    Review, Journal:  Refractory Celiac Disease. (Pubmed Central) -  Jan 3, 2021   
    This in turn has led to potential novel therapies targeting these factors, one of which has reached the clinical trial stage. The morbidity and mortality associated with type II refractory celiac disease remain significant; however, recent advances in the understanding of the pathophysiology of this condition have led to potential therapeutic options that should be investigated.
  • ||||||||||  dexamethasone / Generic mfg., budesonide / Generic mfg.
    Journal:  Janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors. (Pubmed Central) -  Dec 20, 2020   
    Steroid administration currently represents the standard treatment for DMD patients, the rationale being based on their anti-inflammatory effects. The findings presented here offer new insights on additional glucocorticoid effects on muscle stem cells that may affect muscle homeostasis and physiology.
  • ||||||||||  budesonide / Generic mfg., tamoxifen / Generic mfg., methotrexate / Generic mfg.
    Journal:  Drugs Causing Bone Loss. (Pubmed Central) -  Dec 18, 2020   
    Some drugs such as selective serotonin reuptake inhibitors (SSRI), paracetamol, and non-steroidal anti-inflammatory drugs (NSAIDs) may not per se be associated with bone loss, but fracture risk may be increased, possibly stemming from an increased risk of falls stemming from effects on postural balance mediated by effects on the central nervous system or cardiovascular system.This paper performs a systematic review of drugs inducing bone loss or associated with fracture risk. The chapter is organized by the Anatomical Therapeutic Chemical (ATC) classification.
  • ||||||||||  budesonide / Generic mfg.
    Journal:  Therapy of radiation-induced esophagits by oro-dispersible budesonide (Pubmed Central) -  Dec 16, 2020   
    Radiation esophagitis is a common side effect of therapeutic radiotherapy. In this case report, we describe a patient with a complete remission of the esophagitis after therapy with an oro-dispersible budesonide formulation.
  • ||||||||||  budesonide / Generic mfg.
    #BudesonideWorks (Twitter) -  Nov 21, 2020